Publications by authors named "A T Bergeman"
Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, potentially life-threatening genetic heart disease. Nonselective beta-blockers (BBs) are highly effective in reducing CPVT-triggered arrhythmic events. However, some patients suffer from unacceptable BB side effects and might require strategies without a BB.
View Article and Find Full Text PDFArticle Synopsis
- The World Health Organization recommends the use of single-dose rifampicin (SDR) for leprosy post-exposure prophylaxis (PEP), potentially reducing leprosy risk by about 50% in contacts of patients.
- A Phase 2 trial tested a new PEP regimen that combines bedaquiline with rifampicin (BE-PEP) against the standard therapy (SDR-PEP), focusing on safety and QT interval changes in patients.
- The trial, involving 313 participants, demonstrated that BE-PEP did not significantly differ from SDR-PEP regarding QT interval changes after treatment, indicating comparable safety profiles between the two regimens.
Article Synopsis
- - Anti-mycobacterial drugs can cause QT interval prolongation, risking serious heart issues, but monitoring is tough in places with high rates of leprosy and tuberculosis.
- - The BE-PEOPLE trial assessed the safety of a bedaquiline regimen while measuring QT intervals before and after treatment using both mobile electrocardiogram (mECG) and standard methods.
- - Results showed that mECG is a feasible and accurate tool for QT interval tracking, with a strong correlation to traditional measurements, although automated readings were generally less precise.
Background: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia.
Methods: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy.
Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.
Card Electrophysiol Clin
September 2023
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by bidirectional or polymorphic ventricular arrhythmia provoked by exercise or emotion. Most cases are caused by pathogenic variants in the gene encoding the cardiac ryanodine receptor (RYR2). The options for treating patients with CPVT have increased during the years, and evidence suggests that these have led to lower arrhythmic event rates.
View Article and Find Full Text PDF